Perspective Therapeutics, INC 8-K filings

Perspective Therapeutics will present data on its cancer therapies, including VMT-NET and other promising treatments, at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting in June.

Perspective Therapeutics announced its first quarter 2024 financial results, along with key clinical and platform developments, including progress in clinical trials and new technology in-licensing.

Perspective Therapeutics has completed the sale of its Isoray Medical subsidiary's assets to GT Medical Technologies, receiving stock and future royalty payments.

Perspective Therapeutics has changed its independent registered public accounting firm from Assure CPA to WithumSmith+Brown, effective immediately on April 5, 2024.

Perspective Therapeutics has extended the termination date of its asset purchase agreement with GT Medical Technologies to April 30, 2024.

Perspective Therapeutics announced its fiscal year 2023 financial results, highlighting significant progress in its radiopharmaceutical programs and strategic partnerships.

Perspective Therapeutics has announced May 31, 2024, as the date for its 2024 Annual Meeting of Stockholders and established deadlines for stockholder proposals.

Perspective Therapeutics has entered into a clinical collaboration with Bristol Myers Squibb to evaluate the combination of their targeted alpha-particle therapy with nivolumab for metastatic melanoma.

Perspective Therapeutics has released an updated corporate presentation, as detailed in a recent 8-K filing.

Perspective Therapeutics has successfully raised $87.4 million through a private placement and acquired a cGMP-compliant manufacturing facility to support its radiopharmaceutical development.

Perspective Therapeutics, Inc. has released an updated corporate presentation on its website, as detailed in a recent SEC filing.

Perspective Therapeutics successfully closed a public offering and concurrent private placement, raising a total of $89.8 million to fund general corporate purposes.

Perspective Therapeutics has released preliminary financial estimates for 2023, including approximately $9.4 million in cash and cash equivalents, alongside announcing a proposed offering of common stock.

Perspective Therapeutics has entered into a series of agreements with Lantheus, including an investment agreement, asset purchase agreement, and option agreement, securing a $33.2 million investment and potential future licensing opportunities.

Perspective Therapeutics has begun recruiting patients for the second dosing cohort in clinical trials for its lead product candidates, [212Pb]VMT--NET and [212Pb]VMT01, after positive safety reviews.

Perspective Therapeutics has released an updated corporate presentation, which is now available on their website.

Perspective Therapeutics has entered into strategic agreements with Lantheus, including a potential $33 million equity investment, a $28 million option agreement, and the acquisition of a radiopharmaceutical manufacturing facility.